Charles River Laboratories (CRL)
Health Care · Contract Research Organization (CRO) · NYSE
Charles River Laboratories is a global, non-clinical contract research organization that partners with life sciences companies to streamline drug discovery and development.
What Charles River Laboratories does
Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development processes. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. Its offerings span the drug development continuum, from early-stage discovery and non-clinical safety testing to specialized manufacturing support and laboratory animal research models.
Themes: drug development outsourcing, pre-clinical research services, life science tools, biotech R&D services
Fundamentals
- Price$298.58 as of 2026-08-24 close
- Market cap$14.3B as of 2026-08-24
- 1-year return+84.5% 2025-08-22 close $161.84 → 2026-08-24 close $298.58
- P/En/a negative earnings
- Net margin-6.0% as of 2026-08-24
- Gross margin+34.6% as of 2026-08-24
- ROE-7.7% as of 2026-08-24
- Debt / equity0.93 as of 2026-08-24
- Revenue growth (YoY)-0.7% as of 2026-08-24
- Revenue CAGR (3y)+0.3% SEC XBRL
- Beta1.36 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How CRL compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CRL is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
50.5 #741 of 1,704 scored · #131 of 240 in Health Care
Trend 84th: a strong uptrend, with buyers in control; volume and participation 80th: it gapped 7.0% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 22nd: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 0% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Charles River Laboratories looks technically
Charles River Laboratories (CRL) is trading 52.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 49, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 76, in overbought territory (above 70). It just made a new 20-day high, pushing above its recent trading range. It is 1.4% below its 52-week high (its highest price of the past year).
Trend
7
| Distance from the 200-day | it is trading 52.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +52.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $234.10 | $234.10 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $193.89 | $193.89 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 36 trading days ago — a "golden cross", a bullish long-term signal | 36 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 49, with buyers in control | 49.4 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 76, in overbought territory (above 70) | 76.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($228.52 to $299.32) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $299.32 | $299.32 |
|---|---|---|
| From the 52-week high | it is 1.4% below its 52-week high (its highest price of the past year) | -1.4% |
| Above the 52-week low | it is 104.6% above its 52-week low (its lowest price of the past year) | +104.6% |
| Below the 52-week high | it is 1.4% below its highest point of the past year | 1.4% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $460.21 (set on 2021-09-24) | $460.21 |
| Given back of the 52-week move | over the past year its closes ranged ($145.57 to $295.19), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $197.94 to $202.72. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 35.9% below its all-time high | -35.9% |
| Nearest price level | it is trading 19.6% above a support level at $237.24 — a price it turned at twice since 2026-07-01, most recently on 2026-07-10. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -19.6% |
| All-time low | its lowest closing price on record is $19.92 (set on 2008-11-21) | $19.92 |
| Above the all-time low | it is 1381.9% above its all-time low | +1,382% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 82% of the past ~6 months) | 82nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $10.67 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $10.67 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $215.75 and $311.50 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $215.75 – $263.63 – $311.50 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 9.5 daily ranges above its 200-day average price (52.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.01× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 5 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.1% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.1% |
|---|---|---|
| Open gap | it gapped 7.0% above the previous close 21 sessions ago and has not traded back through the level it left behind at 218.7 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +7.0% |
| Gap filled | a 2.2% gap up opened on 2026-06-17 has been "filled" 45 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 45 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +5.73% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 32.2 percentage points (the stock gained 34.5% while the market gained 2.3%) | +32.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 82.7 percentage points (the stock gained 85.8% while the market gained 3.1%) | +82.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 63.7 percentage points (the stock gained 74.8% while the market gained 11.1%) | +63.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 70.5 percentage points (the stock gained 91.0% while the market gained 20.5%) | +70.5% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 35% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 8.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +35.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 50% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $197.01 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +49.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $278.91 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +5.8% |
Price levels it has turned at before
CRL last closed at $295.19 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $237.24 | Support | 19.6% below the last close | turned there twice · 2026-07-01 to 2026-07-10 |
| $229.00 | Support | 22.4% below the last close | turned there three times · 2024-11-06 to 2026-01-22 |
| $213.55 | Support | 27.7% below the last close | turned there twice · 2024-09-19 to 2026-07-21 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.75 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$281.00 range $145.00 – $318.00; median $300.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CRL
- Consensus EPS estimate$2.95 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Volatile demand environment in the Discovery and Safety Assessment (DSA) segment","Risks associated with operational restructuring and site optimization initiatives","Dependence on sustained R&D spending from biopharmaceutical clients"]
What changed in the latest 10-Q
AI-assisted comparison of CRL's 10-Q filed 2026-05-07 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references Annual Report on Form 10-K for fiscal year 2025 as filed February 18, 2026 (vs. older filing referencing fiscal year 2024 filed February 19, 2025)
- Newer filing states DSA backlog held consistent at $1.9 billion as of March 28, 2026 and December 27, 2025
- Newer filing describes cost savings initiatives expected to generate approximately $300 million in cumulative, annualized cost savings by end of 2026, with more than $175 million benefitting fiscal year 2025
- Newer filing reports restructuring charges of $31.6 million during three months ended March 28, 2026, and $99.8 million and $107.0 million during fiscal years 2025 and 2024
- Newer filing discloses acquisition of additional 79% equity interest in PathoQuest SAS completed April 17, 2026 for €51.6 million (approximately $60.0 million), resulting in 100% controlling interest
- Newer filing discloses acquisition of certain assets of K.F. Cambodia Ltd (Cambodian NHP Supplier) completed January 14, 2026 for $507.3 million ($335.0 million at closing and $172.3 million deferred consideration)
- Removed:
- Older filing's statement about cautious spending environment 'related to our global biopharmaceutical and biotechnology clients, as they reassess their budgets, reprioritize their drug pipelines, and manage their cost structures' is removed and replaced with 'as the challenging demand environment experienced in the recent prior quarters has persisted'
- Older filing's DSA backlog figures ($1.8 billion as of September 27, 2025 from $2.0 billion as of December 28, 2024) are replaced with different dates and figures
- Older filing's description of restructuring actions undertaken across North America, Europe and Asia is removed in newer filing
- Older filing's restructuring charges breakdown ($17.3 million and $73.3 million for three and nine months ended September 27, 2025) is removed
- Older filing's 'Strategic Review' section describing November 2025 Board announcement regarding divestitures of approximately 7% of estimated 2025 revenue and $70 million annual incremental cost savings is entirely removed from newer filing
- Older filing's 'Recent Government Actions' section discussing July 4, 2025 One Big Beautiful Bill Act and February 2025 tariff announcements is removed from newer filing
- Reworded:
- Older filing states 'we have undertaken and will continue to implement restructuring actions' whereas newer filing states 'we continue to implement cost savings initiatives focused on driving greater efficiencies, as well as restructuring actions that have been implemented over the past three years'
- Older filing references cost savings of 'approximately $225 million of cost savings on an annualized basis' whereas newer filing references 'approximately $300 million in cumulative, annualized cost savings by the end of 2026'
- Notes:
- Text of older filing is truncated at 'In February 2025 the U.S. government announced plans to enact increased tariffs on Canada, C' so full extent of removed content cannot be confirmed
- Newer filing text is truncated at 'Recent Divestitures' section with incomplete text 'The Comp' so full content of that section is not available for comparison
Risk Factors
- Added:
- Reference to unauthorized access incident involving social engineering attack and employee credential compromise (newer filing, 2026-05-07)
- Statement that Company identified incident and activated cyber incident response plan to contain intrusion (newer filing, 2026-05-07)
- Disclosure that Company is ascertaining what information was exfiltrated and whether sensitive/personally identifiable information was compromised (newer filing, 2026-05-07)
- Statement that as of filing date, cybersecurity incident has not had material impact on financial systems, operations or financial condition (newer filing, 2026-05-07)
- Discussion of potential consequences including business disruptions, governmental investigations, private litigation, fines and injunctive relief (newer filing, 2026-05-07)
- Reference to potential reputational harm and loss of customer, employee and business partner confidence (newer filing, 2026-05-07)
- Caveat that no assurance exists that incident or future incidents will not have material impact on future operations (newer filing, 2026-05-07)
- Discussion of third-party software/hardware providers' cybersecurity incident risks and statement that no prior third-party incident has had material impact to Company's knowledge (newer filing, 2026-05-07)
- Reference to customer confidentiality contract provisions and potential exposure from breaches (newer filing, 2026-05-07)
- Discussion of artificial intelligence and machine learning making it more difficult to anticipate and implement protective measures (newer filing, 2026-05-07)
- Reference to Section 1C 'Cybersecurity' in 2025 Form 10-K for processes and practices information (newer filing, 2026-05-07)
- Removed:
- Older Risk Factors section content referencing non-human primate supply limitations, research animal dependency (older filing, 2025-11-05)
- Discussion of Inflation Reduction Act healthcare reform and potential impact on pharmaceutical R&D spending (older filing, 2025-11-05)
- Discussion of changes in local, state, federal and foreign laws and regulations affecting business (older filing, 2025-11-05)
- Discussion of modifications to international trade policy, public company reporting requirements, environmental regulation and antitrust enforcement (older filing, 2025-11-05)
- Discussion of NAMs (non-animal methods) and their potential to replace or reduce animal model usage (older filing, 2025-11-05)
- References to FDA announcements in April and October 2025 regarding animal testing reduction (older filing, 2025-11-05)
- Discussion of recombinant LAL introduction as alternative to live animal-derived LAL (older filing, 2025-11-05)
- Discussion of quarterly operating results variability and influencing factors (older filing, 2025-11-05)
- Discussion of strategic alternatives review process and announced strategic initiatives from November 5, 2025 announcement (older filing, 2025-11-05)
- Reworded:
- Risk Factors section introduction states 'no material changes' except as disclosed below (newer filing, 2026-05-07) versus older filing referencing different specific risk factors
- Notes:
- Older filing shows substantially different Risk Factors content focused on business/operational risks; newer filing focuses on cybersecurity incident disclosure
- Older filing references February 19, 2025 10-K filing date; newer filing references February 18, 2026 10-K filing date
- The two filings appear to present different risk factor sections entirely rather than sequential updates of the same risks
- Newer filing includes Item 2 on Unregistered Sales and stock repurchase information which is not comparable to older filing's risk factor content
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($17M) — 1 selling insider
- Last 180 days0 buys · 1 sell ($17M) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-29. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CRL's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for CRL from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding CRL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,445,849
- Reported value $1,801,909,150
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CRL had 3,419,974 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CRL had 7.16% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.06 days to cover at the same settlement.
- Reported short interest (shares) 3,419,974
- Short interest (% of shares outstanding) 7.16%
- Prior settlement (shares) 3,343,526
- Reported change 2.29%
- Days to cover (reported) 4.06
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- IQVIA (IQV)
- Labcorp (LH)
- Thermo Fisher Scientific (TMO)
- Eurofins Scientific
- WuXi AppTec
- ICON (ICLR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CRL vs…
Frequently asked questions
What does Charles River Laboratories (CRL) do?
Charles River Laboratories provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and academic institutions accelerate their research and drug development processes. The company operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
What sector is Charles River Laboratories (CRL) in?
Charles River Laboratories (CRL) is classified in the Health Care sector. Its industry is Contract Research Organization (CRO). It trades on NYSE.
Who are Charles River Laboratories's (CRL) competitors?
Notable peers of Charles River Laboratories (CRL) include IQVIA, Labcorp, Thermo Fisher Scientific, Eurofins Scientific and WuXi AppTec. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in CRL?
Yes — we hold 5 matched STOCK Act disclosures for CRL from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Charles River Laboratories (CRL) overbought or oversold right now?
Charles River Laboratories (CRL) is currently in overbought territory (its 14-day RSI is 76, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CRL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.